Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026)
Vericel (VCEL) reported Total Non-Current Liabilities of $127.5 million for Q1 2026, little changed on a YoY basis from $127.3 million in Q1 2025, and down 2.98% sequentially from $131.4 million in Q4 2025.
Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Total Non-Current Liabilities data on file, last reported at $127.5 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities changed 0.21% year-over-year to $127.5 million; the trailing twelve-month figure through Mar 2026 stood at $127.5 million (changed 0.21% YoY), and the FY2025 full-year result was $131.4 million, down 6.04% from the prior year.
- Total Non-Current Liabilities declined to $127.5 million in Q1 2026, from $131.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $139.9 million in Q4 2024 to a low of $67.8 million in Q1 2022.
- A 5-year average of $113.4 million and a median of $127.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities soared 61.98% in 2023 and retreated 6.04% in 2025, its largest moves.
- Tracing VCEL's Total Non-Current Liabilities over 5 years: stood at $80.7 million in 2022, then soared by 58.06% to $127.6 million in 2023, then rose by 9.62% to $139.9 million in 2024, then decreased by 6.04% to $131.4 million in 2025, then fell by 2.98% to $127.5 million in 2026.
- Business Quant data shows VCEL's Total Non-Current Liabilities at $127.5 million in Q1 2026, $131.4 million in Q4 2025, and $129.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | 127.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 127.52 Mn |
| Dec 31, 2025 | 131.43 Mn |
| Sep 30, 2025 | 129.74 Mn |
| Jun 30, 2025 | 127.14 Mn |
| Mar 31, 2025 | 127.25 Mn |
| Dec 31, 2024 | 139.88 Mn |
| Sep 30, 2024 | 132.69 Mn |
| Jun 30, 2024 | 133.66 Mn |
| Mar 31, 2024 | 122.61 Mn |
| Dec 31, 2023 | 127.61 Mn |
| Sep 30, 2023 | 113.68 Mn |
| Jun 30, 2023 | 111.76 Mn |
| Dec 31, 2022 | 80.73 Mn |
| Sep 30, 2022 | 70.18 Mn |
| Jun 30, 2022 | 69.98 Mn |
| Mar 31, 2022 | 67.78 Mn |
| Dec 31, 2021 | 73.20 Mn |
| Sep 30, 2021 | 67.32 Mn |
| Jun 30, 2021 | 70.79 Mn |
| Mar 31, 2021 | 71.20 Mn |